SkyePharma Company Description
There's good karma at SkyePharma. The company uses its controlled-release drug delivery technologies for inhaled, oral, and topical drugs to produce more effective versions of already proven therapies. It makes money from partnerships with other pharmaceutical companies, such as GlaxoSmithKline and Sciele Pharma, who seek out SkyePharma's drug delivery expertise. The firm also develops some compounds on its own and then licenses them to others for marketing. Its lead proprietary candidate is Flutiform, an inhaled treatment for asthma and chronic obstructive pulmonary disease (COPD); SkyePharma licensed US marketing rights for the compound to Kos (now part of Abbott Labs) and European rights to Mundipharma.
View the Comprehensive Company Description for SkyePharma
The Company Description provides a historical perspective of SkyePharma's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of SkyePharma's evolution in the marketplace.
